A Phase III Clinical Study of Rezvilutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer
A phase 3 trial of Rezvilutamide run by Jiangsu HengRui Medicine Co., Ltd. in prostate cancer, now recruiting.
Overview
A Phase III Clinical Study of Rezvilutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer is a phase 3 interventional study registered as NCT07241416 by Jiangsu HengRui Medicine Co., Ltd., with 206 participants planned, started 2025-12-05. Conditions listed: Metastatic Hormone-sensitive Prostate Cancer (mHSPC). No results are recorded here; the registry entry is the source.
Setting
A Multicenter, Randomized, Open-Label, Positive-Controlled Phase III Study of Rezvilutamide Combined With Androgen Deprivation Therapy (ADT) Versus Enzalutamide Combined With ADT for Treating Low-volume Metastatic Hormone Sensitive Prostate Cancer (mHSPC)
Phase
Phase 3
Sponsor
Jiangsu HengRui Medicine Co., Ltd.
Registry
Enrolled
206
Similar pages
not linked directly; found by shared links- TrialA Clinical Study of SHR-4394 in Combination With Anti-tumor Therapy in Prostate Cancer
Shares Rezvilutamide, Jiangsu Hengrui Pharmaceuticals, Prostate cancer.
- TrialA Study of SHR3680, HS-20093 and SHR2554 in Subjects With Prostate Cancer
Shares Rezvilutamide, Jiangsu Hengrui Pharmaceuticals, Prostate cancer.
- TrialA Study for the Treatment of Metastatic Prostate Cancer With HRS-1167 Tablets Combined With Abiraterone Acetate Tablets and Prednisone
- TrialA Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Ver
- TrialA Phase III Study Comparing HRS-4357 With Novel Androgen Receptor Pathway Inhibitors in Patients With Progressive, PSMA-Positive Metastatic Castration-Resistant Prostate Cancer
- TrialA Study of HRS-5041 Tablets Combined With Antitumor Therapy in Subjects With Advanced Prostate Cancer
- TreatmentHRS-4357
- TreatmentHS-20093